KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Gains from Sales and Divestitures (2010 - 2021)

Abbott Laboratories recorded quarterly Gains from Sales and Divestitures of $6.5 million in Q4 2021, down 9.21% quarter-over-quarter from $7.2 million in Q4 2020, and down 9.21% year-over-year from $7.2 million in Q4 2020.

Abbott Laboratories' Gains from Sales and Divestitures history runs 12 years deep, the most recent figure standing at $6.5 million for Q4 2021.

  • In Q4 2021, Gains from Sales and Divestitures fell 9.21% year-over-year to $6.5 million; the TTM figure through Dec 2021 stood at $6.5 million (down 9.21% YoY), while the FY2021 annual figure was $6.5 million, down 9.21% from the prior year.
  • Gains from Sales and Divestitures came in at $6.5 million for Q4 2021 at Abbott Laboratories, down from $7.2 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $7.8 million in Q4 2019 to a low of $6.5 million in Q4 2021.
  • A 5-year average of $7.3 million and a median of $7.5 million in 2018 frame the typical range for Gains from Sales and Divestitures.
  • Across the five-year window, Gains from Sales and Divestitures gained 29.29% in 2017 and retreated 9.21% in 2021, its largest moves.
  • Abbott Laboratories' Gains from Sales and Divestitures stood at $7.6 million in 2017, then declined by 0.42% to $7.5 million in 2018, then increased by 3.03% to $7.8 million in 2019, then retreated by 7.52% to $7.2 million in 2020, then retreated by 9.21% to $6.5 million in 2021.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $6.5 million, $7.2 million, and $7.8 million for Q4 2021, Q4 2020, and Q4 2019 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Zimmer Biomet Holdings 16.17 Bn 15.75 Bn 1.51 Bn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 6.51 Mn
Dec 31, 2021 6.51 Mn
Dec 31, 2020 7.17 Mn
Dec 31, 2020 7.17 Mn
Dec 31, 2019 7.75 Mn
Dec 31, 2019 7.75 Mn
Dec 31, 2018 7.52 Mn
Dec 31, 2018 7.52 Mn
Dec 31, 2017 7.55 Mn
Dec 31, 2017 7.55 Mn
Dec 31, 2016 5.84 Mn
Dec 31, 2016 5.84 Mn
Dec 31, 2015 6.69 Mn
Dec 31, 2015 6.69 Mn
Dec 31, 2014 7.20 Mn
Dec 31, 2014 7.20 Mn
Dec 31, 2013 7.82 Mn
Dec 31, 2013 7.82 Mn
Dec 31, 2012 6.77 Mn
Dec 31, 2012 6.77 Mn
Dec 31, 2011 5.00 Mn
Dec 31, 2011 5.00 Mn
Dec 31, 2010 3.78 Mn
Dec 31, 2010 3.78 Mn